Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GLS | O94925 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414683 | 0.72 | ACP1 (0.58) | ALDH1A1 | |
| SCHEMBL11685658 | 0.69 | MAPT (0.43) | MAPTGLSALDH1A1L3MBTL1TAAR1 | |
| SCHEMBL9481584 | 0.68 | MEN1 (0.39) | MAPTALDH1A1L3MBTL1CA1CA2 | |
| SCHEMBL751121 | 0.66 | PARP1 (0.39) | MAPTALDH1A1L3MBTL1TAAR1PARP1 | |
| SCHEMBL11254531 | 0.66 | MAPK1 (0.49) | MAPTALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL5912479 | 0.66 | NPC1 (0.55) | MAPTALDH1A1 | |
| SCHEMBL29353446 | 0.65 | KAT8 (0.61) | MAPTGLSALDH1A1 | |
| SCHEMBL3572439 | 0.63 | MAPT (0.36) | MAPTGLSALDH1A1L3MBTL1TAAR1 | |
| SCHEMBL29362473 | 0.62 | ALDH1A1 (0.65) | MAPTGLSALDH1A1L3MBTL1 | |
| SCHEMBL1355797 | 0.62 | MAPT (0.57) | MAPTALDH1A1L3MBTL1TAAR1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | claimed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | claimed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | claimed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | claimed |
| US-20040116439-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2004-06-17 | — | — | US | claimed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | claimed |
| EP-1343561-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-09-17 | — | — | EP | claimed |
| EP-1294691-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-03-26 | — | — | EP | claimed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | claimed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| EP-1343561-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1343561-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-1294691-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002047762-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001096305-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | MAPT 4785/4885GLS 2090/4885ALDH1A1 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.